Proteomics International’s Post

🔬 Highlights from the Combined Biological Sciences Meeting 2024 🔬 We had a fantastic time at the Combined Biological Sciences Meeting 2024, held at the University of Western Australia. It was an invaluable opportunity to connect with passionate students and researchers who are driving the future of biological sciences. Engaging with the next generation of scientists allowed us to showcase our cutting-edge analytical service offerings and explore how we can support their research journeys. We are inspired by the enthusiasm and innovative ideas shared during our conversations and look forward to fostering these connections. Thank you to everyone who visited us at Booth No. 16. We are excited about the possibilities ahead! #ProteomicsInternational #CBSM2024 #ScientificCommunity #StudentEngagement #BiologicalSciences #Diagnostics #AnalyticalServices

As the digitisation of healthcare continues to advance at rapid speed, consumers are increasingly able to tailor their healthcare services to their specific and very personal needs. Managing Director Dr Richard Lipscombe wrote an opinion piece for Medhealth Insight recently, looking at how healthcare providers and developers can combine this digitisation with advances in technology to offer precision medicine solutions, particularly in areas where there is an unmet medical need. You can read more here - https://lnkd.in/gMBX4xPt #PIQ #precisionmedicine #personalisedhealthcare #medicaldevices #opinionpiece #promarkerplatform #digitalhealth #futurehealthcare #prognostics #diagnostics #biotechnology #healthcaretechnology

Proteomics International recently announced the PromarkerD test for predicting renal decline has been tested in patients with type 1 diabetes for the first time, with the groundbreaking study demonstrating high accuracy for predicting chronic kidney disease. The results are a significant advancement and highlights the versatility and robustness of the PromarkerD test, which has been validated for predicting renal decline in type 2 diabetes, at a time when global authorities are continuing to sound the alarm about the economic, social and health impact of the condition. The findings were presented at the recent Australasian Diabetes Conference in Perth and have been accepted for publication in the journal of Clinical Diabetes and Endocrinology. You can read the Medical Forum’s interview with lead author, endocrinologist at Fremantle Hospital and UWA Professor of Medicine, Dr Tim Davis - https://lnkd.in/gT8rHZ55 Read the full announcement here - https://lnkd.in/g2JK344n #ASX #PIQ #diabetes #Type1Diabetes #PromarkerD #EarlyDiseaseDetection #prognostics #diagnostics #DiabeticKidneyDisease #ChronicKidneyDisease #24ADC

September is Pain Awareness Month: Spotlight on Pelvic Pain and Endometriosis This September, we’re raising awareness about pelvic pain, focusing on endometriosis - a condition affecting 1 in 9 girls and women worldwide. Endometriosis causes tissue similar to the uterine lining to grow outside the uterus often leading to pain in the stomach, back and hip areas which can significantly impact quality of life. Despite its impact, it can take 4 to 11 years to receive diagnosis from the onset of symptoms, leaving many without effective care and enduring ongoing, unexplained pain. At Proteomics International, we are in the late stages of developing PromarkerEndo, a simple blood test enabling earlier diagnosis of endometriosis. The test has analysed over 1,000 samples, accurately diagnosing more than 90% of those with endometriosis. Read more about PromarkerEndo in the PIQ 2024 Annual Report, from page 18 - https://lnkd.in/gS3vYp9C #PainAwarenessMonth #EndometriosisAwareness #PelvicPain #ChronicPain #HealthAwareness #EarlyDiagnosis #PromarkerEndo

A new study published in the journal Cancer estimates the number of cancer cases among men is to rise 84% to 19 million globally and by 2050 with the number of deaths expected to rise more than 90% to 10.5 million. Esophageal cancer was also highlighted as one of three cancers to have the highest mortality-to-incidence ratio, a statistic that is often attributed to a lack of symptoms in the early stages. Proteomics International is continuing to progress its PromarkerEso diagnostic blood test for oesophageal adenocarcinoma and the pre-malignant condition Barrett’s oesophagus, with the aim of detecting the disease sooner and improving long-term survival rates. You can read more about the cancer research here - https://lnkd.in/geMpGr4s And more about PromarkerEso here - https://lnkd.in/gKz6xdyz #cancer #earlydetection #diagnostics #Biotechnology #HealthcareTechnology #PromarkerEso #oesophagealcancer #esophagealcancer #futurehealthcare 

🧪 𝗣𝗞 𝗧𝗿𝗶𝘃𝗶𝗮 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲! 🧠 𝗧𝗵𝗶𝗻𝗸 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄 𝘁𝗵𝗲 𝗮𝗻𝘀𝘄𝗲𝗿? Drop it in the comments below! 👇 Let’s test your PK knowledge! 💡 𝗛𝗶𝗻𝘁: Cmax is a critical factor in determining the effectiveness and safety of a drug. Stay tuned for the correct answer and discover how our PK services can help you leverage such insights for successful drug development. Email us at info@proteomics.com.au to get a PK quote for your upcoming clinical study. #Pharmacokinetics #PKTrivia #Cmax #DrugDevelopment #ClinicalTrials #ProteomicsInternational

Fresh research out of the UK has again highlighted chronic kidney disease (CKD) as being a global health issue that remains underdiagnosed and undertreated and is predicted to become the fifth leading cause of death globally by 2050. Proteomics International recognises there is a significant need for improved diagnosis and prevention of CKD and is continuing to progress the commercialisation of the PromarkerD blood test to predict the risk of diabetic kidney disease in people with diabetes. To read more about the rollout of PromarkerD in Europe, the UK and other areas globally, check out our Annual Report - https://lnkd.in/gS3vYp9C Read the latest article out of the UK on CKD here - https://lnkd.in/gBTRzsSn #chronickidneydisease #earlydiseasedetection #ckd #PromarkerD #prognostics #diagnostics #diabetes #diabetickidneydisease #dkd #PIQ #ASX #annualreport

Last week Proteomics International attended the #ADC conference here in Perth. The event was a fabulous opportunity to present the company’s ground-breaking study on type1 diabetes titled "Application of a validated prognostic protein biomarker test for renal decline in type 2 diabetes to type 1 diabetes: The Fremantle Diabetes Study Phase II". https://lnkd.in/g2JK344n Results show PromarkerD, previously validated for predicting renal decline up to four years in advance in type 2 diabetes, now demonstrates high accuracy in predicting Chronic Kidney Disease (CKD) in patients with type 1 diabetes. The study addresses a significant gap in the medical field, focusing on the lack of prognostic biomarkers for CKD in individuals with type 1 diabetes. The results were presented by Professor Tim Davis at the conference. #ADC24 #PromarkerD #diabetes #predictive #type1diabetes #type2diabetes #DiabetesManagement #DiabeticKidneyDisease #ChronicKindeyDisease #diagnostic #prognostic #biomarkers #Proteomics 

🚨 𝗘𝘃𝗲𝗻𝘁 𝗔𝗹𝗲𝗿𝘁: 𝗖𝗼𝗺𝗯𝗶𝗻𝗲𝗱 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟰 Proteomics International is excited to be part of the Combined Biological Sciences Meeting on the 𝟯𝟬𝘁𝗵 𝗼𝗳 𝗔𝘂𝗴𝘂𝘀𝘁 𝟮𝟬𝟮𝟰 at the University of Western Australia’s Club at Perth! Join us at 𝗕𝗼𝗼𝘁𝗵 𝗡𝗼. 𝟭𝟲 to explore our cutting-edge proteomics services. See What We Have in Store: • 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 & 𝗠𝗮𝘀𝘀 𝗦𝗽𝗲𝗰𝘁𝗿𝗼𝗺𝗲𝘁𝗿𝘆: Discover our advanced analytical capabilities. • 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆: Learn about our Promarker™ platform. • 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀/𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗧𝗲𝘀𝘁𝗶𝗻𝗴: Explore our expertise in biologics/biosimilar characterization. • 𝗪𝗔𝗣 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀: Explore our special service rates for WA academic researchers. • 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰: Get insights into our PromarkerD test. Let’s connect and discuss how we can support your R&D goals! #ProteomicsInternational #CombinedBiologicalSciencesMeeting #Proteomics #MassSpectrometry #Biotech #AnalyticalServices